



Management of Neuroendocrine Neoplasms

Guest Editor:

Prof. Dr. Sylvia L. Asa

Department of Pathology, Case
Western Reserve University and
University Hospitals Cleveland,
Cleveland, OH 44106, USA

Deadline for manuscript
submissions:

closed (31 December 2019)

Message from the Guest Editor

Dear Colleagues,

Neuroendocrine neoplasms are increasing in incidence. The complexity of these tumors is manifested in their dual impact on patients: Not only do they grow and metastasize like other cancers, but they also make hormones that result in clinical syndromes, causing signs and symptoms that impact quality of life. Because they tend not to be rapidly proliferative, the usual approach to these tumors with chemotherapeutic agents has not been successful. However, recent advances in understanding the genetic and epigenetic alterations that underlie neuroendocrine tumors provide novel approaches to their treatment, while also clarifying the role of genetic screening for early detection. In this Special Issue, experts in this field will review the current approaches to the management of patients with the spectrum of neuroendocrine neoplasia.

Prof. Dr. Sylvia L. Asa

Guest Editor





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)